Skip to main content
Liminatus Pharma, Inc. logo

Liminatus Pharma, Inc. — Investor Relations & Filings

Ticker · LIMN ISIN · US53271X1081 US Manufacturing
Open in API
Filings indexed 85 across all filing types
Latest filing 2026-06-03 Capital/Financing Update
Country US United States of America
Listing US LIMN

About Liminatus Pharma, Inc.

http://liminatuspharma.com/

Liminatus Pharma, Inc. is a pre-clinical-stage biopharmaceutical company focused on developing novel, immune-modulating cancer therapies. The company specializes in immuno-oncology and is pioneering the development of a second-generation CD47-blockade antibody. This therapeutic approach is designed to utilize the patient's immune system to target and destroy cancer cells. Its lead clinical candidate, IBA101, is a humanized anti-CD47 antibody being advanced toward clinical trials for the treatment of various cancers.

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 92% confidence The document is a United States SEC Form 8-K “Current Report” describing the entry into a material definitive agreement for a warrant exercise inducement offer, issuance of new warrants in a private placement, and related financing activities. This is not an earnings release, management change, or proxy; rather, it is a financing/capital structure update. Therefore, it falls under the Capital/Financing Update category.
2026-06-03 English
424B3
Share Issue/Capital Change Classification · 85% confidence The document is a Form 424B3 prospectus supplement to an S-1 registration statement for a securities offering by Liminatus Pharma, Inc. It amends and updates the terms of the new shares and warrants being issued (a capital raising transaction). This clearly falls under a share issuance/capital change announcement rather than a traditional annual or quarterly report. According to the definitions, this best matches “Share Issue/Capital Change” (SHA).
2026-06-03 English
FORM 8-K
Delisting Announcement Classification · 98% confidence The document is a Current Report on Form 8-K filed under Item 3.01 “Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing,” detailing that the company’s securities will be delisted from Nasdaq. This matches the definition of a Delisting Announcement (DLST).
2026-05-27 English
FORM 8-K
M&A Activity Classification · 92% confidence The document is a Form 8-K Current Report under Item 1.01 (“Entry into Material Definitive Agreement”) describing the terms of a merger agreement and acquisition of InnocsAI by Liminatus Pharma. This is an announcement and detailed description of an M&A transaction. According to the filing definitions, this falls under M&A Activity (Code: TAR).
2026-05-20 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-15 English
10-K - Liminatus Pharma, Inc. (0001971387) (Filer)
Annual Report
2026-03-31 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.